Is Alnylam a rare disease company?
Alnylam Publishes Its 1st-Ever Rare Disease Trend Report | Alnylam® Newsroom.
Is Alnylam a good company?
Alnylam Pharmaceuticals is a great company to work for. It is consistently ranked as one of the top companies to work for in Boston. The company is located in Cambridge Massachusetts right by the Kendall/MIT stop.
Is Alnylam an acquisition target?
Alnylam Pharmaceuticals is a prime potential buyout target for Novartis, Bloomberg reported, citing people with knowledge of the matter. The revelation coincides with Novo Nordisk’ announcement that it is shelling out $3.3 billion to purchase clinical-stage RNAi biotech Dicerna Pharma.
Who founded Alnylam?
Phillip Allen Sharp
How do you pronounce Alnylam Pharmaceuticals?
AL-NY-LAM. Our name may not be the easiest to pronounce, but once you learn it, you’ll never forget it.
Who is Dr John Maraganore?
Dr. John Maraganore is a Senior Advisor at General Atlantic, providing strategic support and advice to the firm’s investment teams and portfolio companies in the Life Sciences sector. Since 2002, Dr. Maraganore has served as the CEO of Alnylam, a biopharmaceutical company focused on RNAi therapeutics.
How many employees does Alnylam have?
Alnylam has over 1,400 full-time employees worldwide as of March 2020.
Who Will Novartis buy?
In 2019, Novartis agreed to buy Medicines Co. and heart drug inclisiran for $9.7 billion. Narasimhan said in a 2019 interview that he wanted to consistently spend the equivalent of about 5% of Novartis’s market value on deals each year. That’s about $10 billion today.
Will Alnylam be acquired?
Alnylam (ALNY) was likely also on the the mover after Novo Nordisk (NYSE:NVO) agreed to acquire Dicerna (NASDAQ:DRNA) for more than $3B. ALNY is focused on RNAi therapies, similar to Dicerna….ALNY Ratings.
When did Alnylam go public?
When did Alnylam go public? Alnylam started trading publicly in May 2004.
What is an Alnylam clinical trial?
Alnylam is committed to developing new, innovative medicines to treat diseases with high unmet medical need. A clinical trial involves research using human volunteers (trial participants, including healthy volunteers or patients), and is intended to answer specific questions about potential new treatments for certain diseases.
What is Alnylam best known for?
Alnylam Is the Leading RNAi Therapeutics Company. Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an entirely new class of medicines. In 2018, our first medicine, ONPATTRO® (patisiran), became the world’s first approved RNAi therapeutic.
What is Alnylam doing with RNAi?
Alnylam is leading the translation of RNAi (RNA interference) into a whole new class of innovative medicines to potentially address the needs of patients who have limited or inadequate treatment options.